Arthur J. Gallagher & AJG
Financial Services · Insurance - Brokers · Synthos Deep Dive · 2026-08-04
The Overview
When a company needs insurance — for its buildings, its trucks, its employees, its liabilities — it usually does not go to an insurer directly. It goes to a broker, who knows the market, negotiates the terms, and takes a commission. Gallagher is the third-largest such broker in the world.
It is a good business for boring reasons. Policies renew every year, so the revenue comes back. The broker does not take the risk — if the insurer pays out a fortune after a hurricane, that is the insurer's problem, not Gallagher's. And it requires almost no equipment: Gallagher spent $145 million on capital projects last year against $13.9 billion of revenue.
Last year Gallagher did something very large. It bought a company called AssuredPartners, spending $15.7 billion and issuing 16% more shares to pay for it. Before the deal it had more cash than debt. After it, it owes about $11.3 billion net.
Two warnings about the numbers you will see quoted elsewhere.
The first is about debt. Standard data feeds show Gallagher with almost no net debt. That is wrong, and the reason is specific to brokers. When a client pays an insurance premium, the money sits in Gallagher's bank account for a while before it reaches the insurer. At the last count that was $7.1 billion of other people's money. It appears as cash — but Gallagher cannot spend it. Strip it out and the company is carrying about 2.9 times its annual earnings in debt, not almost none.
The second is about profit. Gallagher reported about $6.04 per share of profit under standard accounting rules over the last year, and tells investors the "adjusted" figure is about $12.01 — nearly double. The difference is an accounting charge for the value of the customer relationships it bought. That charge is not cash, so excluding it is normal and defensible. But it is worth saying out loud: the company spent $15.7 billion buying those relationships, and it excludes the cost of writing them down.
Something we can report as genuinely clean: we check every company's capital-spending figure against its filings because that number is wrong in four out of ten of the files we examine. Gallagher's is exactly right in all three years we could test, and the company even tells you next year's — about $227 million.
The shares cost $248.36, about 17 times what analysts expect Gallagher to earn in 2027. That is not expensive for this kind of business. Our fair value estimate is $268, about 8% above the price. Analysts say $278.89.
One more thing, and it is unusual enough to state plainly. We maintain a database of 52,021 opinions from independent analysts and commentators. Not one of them mentions this company, or insurance broking at all. So unlike every other company in this batch, we have no outside opinion to check ourselves against. We are relying entirely on the filings. That is why we are cautious.
- Downside Risk 6/10. Very defensive business, meaningfully levered balance sheet, negative tangible book.
- Growth Quality 7/10. Fast, and bought. The underlying rate is high single digits.
- Exponential Potential 2/10. A compounding roll-up in a slow, permanent industry.
Putting a number on it: our fair-value estimate is $268 against a current price of $267.56 — real upside if our numbers are right.
Our summary metrics
"Rated 6 — a genuinely defensive, fee-based, recurring business that has just taken on the largest acquisition in its history and the balance sheet shows it. The supports: a beta of 0.508, the second-lowest in this batch; commission and fee revenue from insurance placement, which recurs on renewal and does not carry underwriting risk; geographic revenue that ties to the income statement to the dollar with the United States at 67.4%; capital expenditure of only $145 million against $13,942 million of revenue, 1.0%; a dividend raised annually; and a 20.0% consensus revenue growth rate for 2026. Against that, five specific exposures. ONE, leverage that the payload materially understates: corporate borrowings of $12,717 million against corporate cash of $1,413 million at 2026-03-31 is $11,304 million of net debt, roughly 2.85x trailing EBITDA — against a vendor reading of 0.159x that is contaminated by $7,069 million of fiduciary cash belonging to clients. TWO, negative tangible book value: goodwill of $22,593 million and intangibles of $10,684 million total $33,277 million against total equity of $23,321 million, so `tangibleBookValuePerShareTTM` is MINUS $36.98 and `tangibleAssetValueTTM` is MINUS $9,491 million. THREE, an enormous gap between GAAP and adjusted earnings: trailing GAAP diluted EPS is approximately $6.04 against an adjusted $12.01 — the adjusted figure is 1.99x the reported one, and the bridge is $1,122.5 million of annual amortisation of acquired intangibles. FOUR, integration risk on a transaction that consumed $15,749 million of net acquisition spend and raised the share count 16.3% in a single year. FIVE, the knowledge base offers no independent check on any of it."
"Rated 7 — the growth is fast, it is bought, and the organic component cannot be separated from the filings in this archive. Revenue: $7,009M (FY2020), $8,209M, $8,551M, $10,072M, $11,555M (FY2024), $13,942M (FY2025) — a 14.7% compound rate over five years, of which a large share is acquisition. Fiscal 2025 alone grew 20.7%, and the cash flow statement shows $15,749 million of net acquisition spend in the same year, so the growth and the spending are the same event. Consensus wants revenue of $16,736M (FY2026), $18,236M (FY2027) and $19,939M (FY2028) — 20.0%, 9.0% then 9.3% — with adjusted EPS of $13.243, $14.908 and $16.760, roughly 12.6% then 12.4% growth. The 20.0% figure for 2026 is the annualisation of a deal that closed part-way through 2025; the 9% figures thereafter are the honest underlying rate. Against a 12-month share price return of MINUS 12.6% while the index rose 24.3%, the market is plainly not paying for the acquired growth. What holds this at 7 rather than higher: the geographic mix is 67.4% United States and the second-largest market, the United Kingdom at 17.8%, grew 11.3% — so this is a mature-market business compounding at high single digits organically; the quarterly revenue series is highly seasonal, ranging from $3,586M to $4,758M across the last four quarters; and the archive contains no organic-growth disclosure, because the CFO Commentary and Supplemental Quarterly Data the 8-K refers to are hosted on the company's website rather than filed."
"Rated 2 — an excellent business with no exponential characteristic, and the dive will not invent one. Gallagher places insurance on behalf of clients and collects a commission or fee; it also runs a third-party claims-administration business. The revenue recurs because policies renew, the margin is protected because the service is advisory rather than capital-intensive, and the growth comes from three sources: the underlying rate of premium inflation, share gained from smaller brokers, and acquisition. Only the third is fast, and it is the one that costs $15,749 million and 16.3% of the share count. The `seg_geo` block shows the shape precisely: United States $9,391M, United Kingdom $2,477M, Other Foreign $886M, Australia $586M, Canada $395M, New Zealand $207M — mature English-speaking commercial insurance markets, none of them a new curve. The one genuinely novel item in the entire archive is a note that fiscal 2025 clean-energy operating results relate to 'investments in new clean energy projects, primarily fusion and carbon sequestration projects', which is a tax-credit structure rather than an operating business and is disclosed as a reconciling item. A 2: a compounding roll-up in a slow, permanent industry."
What does “fair value” mean?
Fair value is Synthos’s estimate of what one share is worth today, based on our model of the company’s future cash generation and the risks to it. It is not a price target or a prediction of where the stock trades next quarter — it’s the price where we think risk and reward are balanced. Above it, you’re paying for outcomes better than our base case; below it, the market is offering a margin of safety.
The model’s inputs and weightings are proprietary — they’re the product. What we publish is the output, plus an independent, public-math cross-check further down the page (“Check our number”) so you can judge it for yourself.
What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
The Road Ahead
What we expect to matter in each window, and the evidence that would prove us wrong.
Short term 0-6 months
Neutral- Driver
- "Gallagher closed 2026-08-04 at $248.36, up 0.23% or $0.57, on 1,001,659 shares — the thinnest turnover in this batch at roughly $249 million. It opened at $244.90, traded down to $240.82 and closed within 0.2% of the day high of $248.82, so the session recovered 3.1% off its low. The stock reported second-quarter results five days ago, on 2026-07-30: adjusted EPS of $2.84 beat the $2.81 consensus by 1.1%, and revenue of $3,955 million MISSED the $4,005.7 million estimate by 1.3%. The technical position is a recovery in progress: 20.0% below the 52-week high of $310.48 and 29.4% above the low of $192.00, 6.9% above a 50-day average of $232.22 and 5.9% above a 200-day average of $234.51, with RSI at 50.4 — exactly neutral — and MACD at +5.16. Three-month return is +20.0% against SPY's +7.6%, the strongest short-term relative performance in this batch, but twelve-month return is MINUS 12.6% against SPY's +24.3%, and the maximum drawdown from peak over the trailing year was 28.8%. So: a stock that fell hard, has rallied 20% in a quarter, and remains 20% below its high."
- What we’re watching
- "The 2026-10-29 print against a consensus of $3.04 and $4,084.8 million. The revenue estimate has now been missed in two of the last four quarters (−1.3% and −0.3%) while adjusted EPS beat in three of four, which is the signature of a company managing costs through a softer top line — watch whether that pattern continues. Watch for the first clean disclosure of organic growth excluding AssuredPartners: the 8-K of 2026-07-30 refers to 'Supplemental Quarterly Data' and 'CFO Commentary' hosted on the company's website, and NEITHER is in this archive, so the single most important operating metric for a broker is unavailable to this dive. Watch capital expenditure against the 10-K's own 2026 guidance of approximately $227 million, up 56.6% from $145 million. And watch the board: the Lead Independent Director died on 2026-07-22, the board reduced itself from nine members to eight on 2026-07-23, and a successor Lead Independent Director was elected."
- Confidence
- Low
Medium term 6-24 months
Tailwind- Driver
- "The medium term is the AssuredPartners integration converting into earnings, and the consensus is explicit about the shape. Revenue is expected to rise 20.0% in 2026 to $16,736 million — the annualisation of a deal that closed part-way through 2025 — then 9.0% and 9.3%. Adjusted EPS is expected to rise 12.6% to $14.908 in 2027 and 12.4% to $16.760 in 2028, against a price of $248.36 that is 18.8x, 16.7x and 14.8x those figures. The mechanism is legible: brokerage is a fee business whose costs are mostly people, so an acquired book of business placed onto an existing platform carries a high incremental margin, and the amortisation of the acquired intangibles — $1,122.5 million in fiscal 2025 — is non-cash and is what separates the $6.04 of trailing GAAP earnings from the $12.01 of adjusted. Free cash flow, recomputed as filed operating cash flow of $1,930 million minus filed capital expenditure of $145 million, was $1,785 million in fiscal 2025, a 2.80% yield, and that figure was depressed by acquisition costs. The deleveraging path matters as much as the earnings: corporate net debt of $11,304 million at roughly 2.85x EBITDA is high for this company historically, and every year of retained cash flow reduces it."
- What we’re watching
- "Whether organic revenue growth — invisible in this archive — holds in the mid-single digits as the property and casualty pricing cycle matures. Whether the adjusted-to-GAAP gap narrows as the acquired intangibles amortise: a company reporting adjusted earnings at 1.99x its GAAP earnings is asking for a great deal of trust. Whether corporate leverage falls from roughly 2.85x, and whether the vendor data ever separates fiduciary cash from corporate cash. Whether the share count stabilises after rising 16.3% in one year to fund the deal. Whether capital expenditure at the guided $227 million for 2026 is a one-year step or a new baseline. Whether the company resumes share repurchases — `commonStockRepurchased` reads exactly zero in all four years of the cash flow file, which for a company of this size is a deliberate choice, not a defect. And whether a fourth-quarter or annual filing discloses AssuredPartners revenue separately, which nothing in this archive does."
- Confidence
- Low
Long term 2+ years
Tailwind- Driver
- "Long-run, insurance broking is one of the better permanent businesses in listed equity and Gallagher is the third-largest practitioner of it. Commissions recur on renewal; the client relationship is sticky because switching brokers means re-tendering an entire insurance programme; the capital intensity is trivial at 1.0% of revenue; and the industry remains fragmented enough that a disciplined acquirer can compound by consolidation for a very long time — Gallagher has done exactly that, taking revenue from $7,009 million in 2020 to $13,942 million in 2025. The economics do not depend on underwriting: the broker is paid whether or not the insurer makes money, which is why the beta is 0.508. Chief executive J. Patrick Gallagher Jr. runs a company bearing his family name, which historically has correlated with long-horizon capital allocation. Against that: the roll-up model requires ever-larger deals to move a $63.8 billion company, and AssuredPartners at $15,749 million of net spend was already large enough to leave the balance sheet at roughly 2.85x EBITDA with negative tangible book value. The mathematical limit of a consolidation strategy is the supply of targets, and the price paid for them rises as the acquirer's need grows."
- What we’re watching
- "Whether the acquisition pipeline supports another decade of consolidation at acceptable prices, or whether AssuredPartners was the last large independent target. Whether the property and casualty pricing cycle — which drives commission revenue directly, since commissions are a percentage of premium — turns and by how much; nothing in this archive quantifies Gallagher's sensitivity to it. Whether goodwill of $22,593 million, now 32.0% of total assets, ever requires impairment. Whether fiduciary assets of $33,873 million, held on behalf of clients, remain a source of investment income as rates move — this is an under-discussed earnings lever for brokers and the archive gives no figure for it. Whether the founding-family leadership transitions cleanly. And whether our knowledge base ever acquires a voice on this industry: at present it holds nothing, which means every future refresh of this dive will be as filings-only as this one."
- Confidence
- Low
Exponential Potential
"Rated 2 — an excellent business with no exponential characteristic, and the dive will not invent one. Gallagher places insurance on behalf of clients and collects a commission or fee; it also runs a third-party claims-administration business. The revenue recurs because policies renew, the margin is protected because the service is advisory rather than capital-intensive, and the growth comes from three sources: the underlying rate of premium inflation, share gained from smaller brokers, and acquisition. Only the third is fast, and it is the one that costs $15,749 million and 16.3% of the share count. The `seg_geo` block shows the shape precisely: United States $9,391M, United Kingdom $2,477M, Other Foreign $886M, Australia $586M, Canada $395M, New Zealand $207M — mature English-speaking commercial insurance markets, none of them a new curve. The one genuinely novel item in the entire archive is a note that fiscal 2025 clean-energy operating results relate to 'investments in new clean energy projects, primarily fusion and carbon sequestration projects', which is a tax-credit structure rather than an operating business and is disclosed as a reconciling item. A 2: a compounding roll-up in a slow, permanent industry."
What could take this further than the base case — and where the market may be underpricing it. Full forward-growth and acceleration math in Deeper analysis, §4 below.
Deeper analysis
Technicals, fundamentals, valuation, and the full expert-claim evidence panel — the detail behind the numbers above.
Reference table
| Street consensus | $278.89 (+12.3%) · median $287 · high $300 (+20.8%) · low $225 (−9.4%) · 19 buy / 9 hold / 1 sell across 29 analysts |
| Valuation | 20.7x trailing ADJUSTED EPS of ~$12.01 · 41.1x trailing GAAP EPS of ~$6.04 · 18.8x FY2026E $13.243 · 16.7x FY2027E $14.908 · 14.8x FY2028E $16.760 (4 analysts) |
| The vendor's leverage figure, corrected | netDebtToEBITDATTM reads 0.159x and enterpriseValueTTM adds only $631M of net debt. The 10-Q shows corporate borrowings of $12,717M against corporate cash of $1,413M — net debt $11,304M, roughly 2.85x trailing EBITDA. The gap is $7,069M of FIDUCIARY CASH — client premiums, disclosed inside $33,873M of fiduciary assets, unavailable to service debt. Corrected enterprise value ~$75,134M, 16.8% above the vendor's |
| Cash generation — recomputed, and verified | FY2025 operating cash flow $1,930M less filed capital expenditure $145M = free cash flow $1,785M, a 2.80% yield. The 10-K states capital expenditure of $145M, $142M and $194M for 2025, 2024 and 2023 — matching the vendor exactly — and guides 2026 to approximately $227M |
| The capex diagnostic that looked corrupt and is not | capexToDepreciationTTM of 0.126 falls below the 0.15 corruption threshold. It is CLEAN: capital expenditure is genuinely $145M while depreciation and amortisation of $1,056M is overwhelmingly amortisation of ACQUIRED INTANGIBLES from a roll-up strategy. Suspicion resolved in the company's favour |
| AssuredPartners, absorbed | $15,749M of net acquisition spend in fiscal 2025 · goodwill $12,270M → $22,593M · intangibles $4,530M → $10,684M · diluted shares 223.9M → 260.3M (+16.3%) · net cash of $1,502M → net debt of $12,604M |
| Tangible book value | MINUS $36.98 per share. Goodwill and intangibles of $33,277M exceed total equity of $23,321M. tangibleAssetValueTTM is MINUS $9,491M |
| Conviction | NONE. ZERO knowledge-base hits out of 52,021 claims — no exact matches, no case-insensitive matches, no text-only matches, nothing discarded. A genuine sector void, reported as empty |
| Technicals | −20.0% from the 52-week high of $310.48; +29.4% above the low of $192.00; +6.9% above the 50-DMA ($232.22) and +5.9% above the 200-DMA ($234.51); RSI 50.4; MACD +5.16; 3-month +20.0% vs SPY +7.6% but 12-month −12.6% vs SPY +24.3%; max drawdown −28.8% |
What the experts actually said
No independent expert claims in the Synthos knowledge base yet for AJG — this dive is fundamentals- and technicals-driven, not panel-driven.
Price & moving averages 12 months · 50 & 200-day averages · 52-week range
Solid line = price · dashed line = 50-day average · dotted line = 200-day average · the two thin horizontal lines mark the 52-week high and low. Price above both averages is an uptrend.
Data summary: last close $267.56, 8% above the 50-day average ($249), 14% above the 200-day average ($234) — an uptrend. 14% below the 52-week high of $310, 39% above the 52-week low of $192.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Data summary: price $267.56 is currently inside the band (band $241–$271).
RSI (14) momentum gauge · 0–100
Above 70 (overbought zone, shaded) = overbought, below 30 (oversold zone, shaded) = oversold. Currently 60.
MACD 12 / 26 / 9 · trend & momentum
The MACD line crossing above the signal line (bars flip to the up color) = momentum turning up; crossing below (bars flip to the down color) = turning down. Bar height = the size of that gap.
Data summary: MACD is currently above its signal line by 0.67, positive momentum.
Relative performance vs S&P 500 & its sector (XLF (sector)), set to 100 a year ago
Solid = AJG · dashed = S&P 500 · dotted = XLF (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
1. The knowledge base is empty, and that is the first finding
A case-sensitive entity sweep on AJG, Arthur J. Gallagher, Gallagher and AssuredPartners, plus free-text searches on "gallagher" and "insurance broker", across all 52,021 distilled claims, returned:
| Count | |
|---|---|
| Raw hits | 0 |
| Exact case-sensitive entity matches | 0 |
| Case-insensitive-only matches | 0 |
| Text-only matches | 0 |
| Discarded | 0 |
Nothing. Not one claim.
Three observations, because the shape of an absence carries information.
First, this is not a matching failure. "Gallagher" is a common surname, and a sweep on a common surname across 52,021 claims would be expected to return false positives if the store contained anything nearby. It returned none — not even a collision to discard. The store does not discuss this company under any spelling, and it does not discuss the industry.
Second, the void is sector-wide. The vendor peer set includes Aon and Marsh & McLennan, the two brokers larger than Gallagher. Commercial insurance distribution is a $100-billion global revenue pool and it is invisible to every source this programme ingests. That is a real gap in the knowledge base and it is worth recording as a coverage finding rather than a Gallagher finding.
Third — and this is the operative consequence — this dive has no qualitative overlay. There is no independent voice on the AssuredPartners integration, no outside read on whether the property and casualty pricing cycle is turning, no counterweight to management's framing, and no one to grade. Every judgement below rests on the filings and the estimate array alone. A conviction rating of "none" is not the same as a neutral rating: it means one of the two legs this programme stands on is missing, and the confidence ratings in the front matter are set to Low across all three horizons for exactly that reason.
2. The leverage figure is wrong by a factor of eighteen, and the mechanism is fiduciary cash
This is the most consequential data finding on the name and it would mislead any screen.
What the payload says:
netDebtToEBITDATTM: 0.159xenterpriseValueTTM: $64,365,320,752 — market capitalisation of $63,734,320,752 plus $631 million of net debtdebtToEquityRatioTTM: 0.0850debtToAssetsRatioTTM: 0.0247
What the 10-Q says at 2026-03-31, in $M:
| 2026-03-31 | 2025-12-31 | |
|---|---|---|
| Cash and cash equivalents (corporate) | 1,413 | 1,396 |
| Fiduciary assets (incl. fiduciary cash of $7,069 and $7,142) | 33,873 | 26,899 |
| Total current assets | 42,019 | 34,356 |
| Corporate related borrowings — current | 640 | 640 |
| Corporate related borrowings — noncurrent | 12,077 | 12,104 |
| Total corporate borrowings | 12,717 | 12,744 |
| Total liabilities | 54,499 | 47,318 |
Corporate net debt at 2026-03-31 = $12,717M − $1,413M = $11,304M. Against trailing EBITDA of approximately $3,967M (from the payload's own 25.18% EBITDA margin on trailing revenue of $15,755M), that is roughly 2.85x — not 0.159x.
The mechanism. An insurance broker collects premiums from clients and remits them to insurers. In between, the money sits on the broker's balance sheet. Gallagher discloses it as a separate line — "Fiduciary assets (includes fiduciary cash of $7,069 in 2026...)" — precisely because it is not the company's money. A data pipeline that nets total cash against total debt counts $7.1 billion of client premiums as debt capacity.
The consequences, all rejected: netDebtToEBITDATTM of 0.159x, debtToEquityRatioTTM of 0.0850, debtToAssetsRatioTTM of 0.0247, enterpriseValueTTM of $64,365M, and every enterprise-value multiple derived from it (evToSalesTTM 4.085x, evToEBITDATTM 16.225x, evToFreeCashFlowTTM 34.560x).
Corrected enterprise value: $63,803.7M market capitalisation + $11,304M corporate net debt + $26M noncontrolling interests = approximately $75,134M — 16.8% above the vendor's figure. Corrected EV/EBITDA is approximately 18.9x, not 16.2x.
Note also the FY2024 balance sheet, which shows the same defect in the other direction. cashAndCashEquivalents reads $14,987.3M at 2025-12-31 — a figure that produced a netDebt of MINUS $1,502.1M, i.e. net cash — while longTermDebt was already $12,731.9M. The company was not sitting on $15 billion of corporate cash; it was holding fiduciary balances plus pre-funding for AssuredPartners. The FY2025 balance sheet then shows cash of $1,396M and net debt of $12,604M — a $14.1 billion swing that a reader would interpret as a catastrophic cash burn rather than a change in how the fiduciary line was captured.
3. AssuredPartners — the transaction that reshaped the balance sheet
The 10-K's XBRL carries AssuredPartners Group LP and AssuredPartners Inc. as named entities with transaction dates of 2024-12-11, 2024-12-19, 2025-01-07 and 2025-08-18 — the announcement, the senior notes issuance, the over-allotment exercise and the closing. The cash flow statement quantifies it: acquisitionsNet of MINUS $15,749 million in fiscal 2025, against $1,462.3 million in fiscal 2024 and $3,032.0 million in fiscal 2023.
What it did to the balance sheet, from bal_a ($M):
| FY2023 | FY2024 | FY2025 | change FY24→FY25 | |
|---|---|---|---|---|
| Goodwill | 11,476 | 12,270 | 22,593 | +84.1% |
| Intangible assets | 4,633 | 4,530 | 10,684 | +135.8% |
| Goodwill + intangibles | 16,109 | 16,800 | 33,277 | +98.1% |
| Total assets | 51,616 | 64,255 | 70,665 | +10.0% |
| Total stockholders' equity | 10,775 | 20,154 | 23,321 | +15.7% |
| Total debt | 8,317 | 13,485 | 14,000 | +3.8% |
| Net debt (as reported) | 7,346 | −1,502 | 12,604 | — |
| Diluted shares (M) | 219.3 | 223.9 | 260.3 | +16.3% |
Two things follow.
Goodwill and intangibles are now $33,277 million against total equity of $23,321 million, so TANGIBLE equity is NEGATIVE $9,956 million. The payload confirms it: tangibleBookValuePerShareTTM of MINUS $36.98 and tangibleAssetValueTTM of MINUS $9,491M. This is not the treasury-stock artefact found elsewhere in this batch; it is a roll-up that has paid book value many times over for customer relationships. priceToBookRatioTTM of 2.68x is therefore flattering — on tangible book the ratio does not exist.
And the amortisation of those intangibles is what separates GAAP from adjusted earnings. inc_a reports fiscal 2025 depreciation and amortisation of $1,122.5 million, up from $842.3 million — a $280 million step in one year — against 260.3 million shares. That is roughly $4.31 per share pre-tax of non-cash charge, and it is the bridge in Section 4.
4. GAAP against adjusted — a factor of two
Gallagher's reported and adjusted earnings differ by more than any name in this batch.
| Quarter | Revenue (inc_q) | GAAP diluted EPS | Adjusted EPS (earn_cal) | ratio |
|---|---|---|---|---|
| Q3 2025 | $3,365.6M | $1.05 | $2.32 | 2.21x |
| Q4 2025 | $3,628M | $0.58 | $2.38 | 4.10x |
| Q1 2026 | $4,758M | $3.16 | $4.47 | 1.41x |
| Q2 2026 | $4,003M | $1.25 | $2.84 | 2.27x |
| Trailing twelve months | $15,754.6M | $6.04 | $12.01 | 1.99x |
At $248.36 that is 41.1x trailing GAAP earnings and 20.7x trailing adjusted earnings. priceToEarningsRatioTTM of 40.67x is the GAAP figure and is technically correct; it is also not the number any analyst uses, and every forward estimate in the file is on the adjusted basis — the FY2025 consensus of $10.69 against a delivered GAAP $5.75 proves it.
We use the adjusted basis for all forward multiples and state the GAAP figure alongside it, because on this name the gap is the argument. The amortisation being excluded is genuinely non-cash. It is also the accounting recognition of $15,749 million that the company actually spent, and a reader who accepts the adjustment without noticing the acquisition spend is being shown growth without its price.
One further observation on the quarterly series: revenue is highly seasonal, ranging from $3,586M to $4,758M across four quarters, with the March quarter the largest — consistent with January renewal concentration in commercial insurance. Any sequential comparison on this name is meaningless and none is drawn.
5. Cash generation — and a capex signature that looked corrupt and is not
This dive was directed to test whether the capital-expenditure datum and its diagnostic fail independently. On Gallagher the diagnostic trips and the datum is clean, which is the case the data contract explicitly warns about.
capexToDepreciationTTM reads 0.1265 — below the 0.15 threshold that flags 344 files in this programme as suspicious.
The 10-K settles it, in prose and in the statement:
> "Capital expenditures were $145 million and $142 million for 2025 and 2024, respectively. In 2025 and 2024 capital expenditures include amounts incurred related to office moves, investments made in IT and software development projects... In 2026, we expect total expenditures for capital improvements to be approximately $227 million, (includes impact of acquisitions closed through December 31, 2025)."
And the cash flow statement: "Capital expenditures | (145) | (142) | (194)".
| Fiscal year | Capex — vendor | Capex — filed | Operating cash flow — vendor | filed | Free cash flow |
|---|---|---|---|---|---|
| FY2023 | $193.6M | $194M | $2,031.7M | $2,032M | $1,838M |
| FY2024 | $141.9M | $142M | $2,582.9M | $2,583M | $2,441M |
| FY2025 | $145.0M | $145M | $1,930.0M | $1,930M | $1,785M |
Both series match to rounding across three years. The low capex-to-depreciation ratio is REAL and it has a clean explanation: Gallagher's depreciation and amortisation of $1,056 million is overwhelmingly amortisation of ACQUIRED INTANGIBLES, not depreciation of physical assets. A roll-up will always show a low capex-to-depreciation ratio, and the signature is diagnostic of the business model rather than of a data error. Suspicion tested and resolved in the company's favour — and the 10-K even supplies the forward number, approximately $227 million for 2026, which is a 56.6% increase and is not in the payload.
Free cash flow of $1,785 million is a 2.80% yield ($1,785M against $63,803.7M), and freeCashFlowYieldTTM of 2.92% is consistent. Note that fiscal 2025's figure fell 26.9% from fiscal 2024's $2,441 million, on transaction and integration costs — so the 2.80% understates the run rate.
Capital return is dividends only. Dividends paid: $429.5M, $473.6M, $525.4M, $667M across FY2022-FY2025 — a 15.8% compound rate. dividendPerShareTTM of $2.70 is a 1.09% yield. commonStockRepurchased reads EXACTLY ZERO in all four years, which on a company of this size is a policy — capital goes to acquisitions, not buybacks — and the 10-K's liquidity section notes that "if liquidity concerns arise, we may be more likely to use common stock to fund acquisitions." Total shareholder yield is 1.09%, the lowest in this batch bar one.
6. Geography — the one segment block that is clean
seg_geo sums to revenue exactly and the home market is present. This is a clean check and it is reported as one.
| Region | FY2025 | share | FY2024 | YoY |
|---|---|---|---|---|
| UNITED STATES | $9,391M | 67.4% | $7,427.9M | +26.4% |
| UNITED KINGDOM | $2,477M | 17.8% | $2,225.4M | +11.3% |
| Other Foreign | $886M | 6.4% | $700.8M | +26.4% |
| Australia | $586M | 4.2% | $574.6M | +2.0% |
| Canada | $395M | 2.8% | $416.0M | −5.0% |
| New Zealand | $207M | 1.5% | $210.2M | −1.5% |
| Total | $13,942M | 100.0% | $11,554.9M | +20.7% |
The block totals $13,942M against inc_a revenue of $13,941.8M — a $0.2M rounding difference, and the UNITED STATES line is present at 67.4%. Both the home-market omission test and the over-counting test pass.
The United States grew 26.4% and Canada shrank 5.0%, which is the acquisition arriving in one market. Australia, Canada and New Zealand together are 8.5% of revenue and are collectively flat.
seg_prod, by contrast, changed taxonomy and mixes two different disaggregations. Through FY2023 it carried the genuine reportable segments — Brokerage, Risk Management and Corporate — summing to revenue exactly ($8,637.2M + $1,433.0M + $1.7M = $10,071.9M for FY2023). From FY2024 it switched to a revenue-type disaggregation and left a residual line still labelled "Brokerage Segment": for FY2025 it reads Commissions $8,024M, Brokerage Segment $4,195M, Investment Performance $769M, Supplemental Revenue $466M and Contingent Revenue $324M, totalling $13,778M against $13,942M of revenue — 98.8%, with $164M unaccounted for. Mixing a segment label with revenue-type labels in the same block makes it unusable for either purpose, and no product analysis is drawn from it.
7. Valuation
At $248.36:
| FY2026E | FY2027E | FY2028E | |
|---|---|---|---|
| Revenue | $16,735.7M (5) | $18,236.3M (6) | $19,939.2M (5) |
| Revenue growth | +20.0% | +9.0% | +9.3% |
| Adjusted EPS | $13.243 (12) | $14.908 (13) | $16.760 (4) |
| EPS growth | — | +12.6% | +12.4% |
| P/E | 18.8x | 16.7x | 14.8x |
| EPS range | $12.762–$13.904 | $14.487–$15.539 | $14.814–$18.958 |
Estimate coverage is asymmetric and worth naming. Thirteen analysts cover FY2027 adjusted EPS but only SIX cover FY2027 revenue, and FY2028 rests on four for EPS and five for revenue. The FY2027 EPS range of $14.487 to $15.539 is a 7.1% spread — tight — while the FY2028 range of $14.814 to $18.958 is 28%. FY2027 is the anchor and FY2028 is a cross-check only.
est.ebitdaAvg and est.ebitAvg are rejected for the fixed-ratio fabrication signature. ebitdaAvg is exactly 24.356% of revenueAvg and ebitAvg exactly 17.121% in FY2025, FY2026, FY2027 and FY2028 alike. A margin constant to three decimal places across four years is a formula. The ordering is at least possible here (EBITDA exceeds EBIT), unlike the impossible variant found on two other names in this batch. All valuation uses epsAvg.
7a. What today's price assumes (the inversion)
At $248.36 — 18.8x FY2026 adjusted consensus and 16.7x FY2027 — the price embeds:
- Adjusted EPS reaches $13.243 in 2026 and $14.908 in 2027. (Consensus; 12 and 13 analysts.) The four quarters in
earn_calsum to $12.01 trailing, so FY2026 needs 10.3% growth on the run rate. Achievable, and the AssuredPartners annualisation supplies most of it. - Revenue rises 20.0% in 2026. (Consensus; only FIVE analysts.) This is the least well-covered load-bearing number on the page, and it is the annualisation of a part-year acquisition rather than an organic forecast.
- Organic growth holds in the mid-single digits. (Our inference; NOT disclosed in this archive.) This is the most fragile assumption in the price and we cannot test it, because the CFO Commentary and Supplemental Quarterly Data that would contain it are hosted on the company's website and are referenced but not filed. A broker's commissions are a percentage of premium, so a softening property and casualty pricing cycle reduces revenue without any loss of clients.
- Leverage of roughly 2.85x EBITDA declines rather than rises. (Our derivation from the 10-Q.) The price contains no visible discount for it because the standard data feed says leverage is 0.159x.
- The market keeps paying 16-20x forward adjusted earnings. (Our number.) At 14x FY2027E the stock is $209; at 20x it is $298. The observed twelve-month range on this estimate — from the 52-week low of $192.00 to the high of $310.48 — is 12.9x to 20.8x.
7b. The return bridge (why the multiple moves)
Expected return over the next twenty-four months decomposes as: adjusted EPS growth (+26.6% cumulative, from FY2026E $13.243 to FY2028E $16.760) + multiple drift (roughly HELD at 17-18x on the then-forward year) + shareholder yield (+1.09% per year) ≈ +12% to +15% a year if the base lands.
Our base of $268 applies 18.0x FY2027E, a modest expansion from today's 16.7x, and that is the fragile leg. At an unchanged 16.7x the fair value is $249 — the current price — so the entire 8.0% base upside is one and a third turns of multiple.
Note what is NOT in the bridge: a buyback. Gallagher has repurchased no stock in four years and has issued 16.3% more shares in the most recent one. The share count is a headwind on this name, not a tailwind, which is unusual for a company of this quality and is a direct consequence of the acquisition strategy.
7c. Variant perception (where we differ, what would surprise)
- We are 3.9% below the street's $278.89 and have no meaningful variant perception on the level. Both numbers sit inside a target range of $225 to $300. Our EPS numbers are the consensus.
- We do differ on the balance sheet, and the difference is factual rather than a judgement. The market is being shown 0.159x leverage by standard data and the filings say roughly 2.85x. Watchable number: corporate borrowings less corporate cash in the next 10-Q, against $11,304 million. A visible deleveraging path is worth a multiple turn on its own.
- We think the GAAP-to-adjusted gap deserves more scepticism than a 1.99x ratio normally receives. The exclusion is legitimate — amortisation of acquired intangibles is non-cash — but the company spent $15,749 million and issued 16.3% more shares to acquire the assets being amortised, and both facts belong in the same sentence.
- We have NO variant perception on business quality, and we also have no independent view of any kind: the knowledge base is empty. We say so rather than manufacturing an edge.
- Positive surprise that would force a re-rate: disclosed organic growth above 6% with the property and casualty pricing cycle intact; corporate net debt below $10 billion; or the resumption of share repurchases, which would signal the acquisition programme is pausing.
- Negative surprise that would break the thesis: organic growth below 3%; a goodwill impairment against the $22,593 million balance; a third consecutive revenue miss after −0.3% and −1.3%; or another large acquisition funded with equity at a share price 20% below the 52-week high.
Synthos fair values
All three anchors are multiples of the FY2027 consensus adjusted EPS distribution (mean $14.90762, low $14.48656, high $15.53921, 13 analysts), cross-checked against the observed twelve-month multiple range of 12.9x–20.8x.
- Bear ~$196 — 13.5x the FY2027 consensus LOW of $14.487. Cross-check: 2.1% above the 52-week low of $192.00; 14.8x FY2026E; a 1.38% dividend yield. The scenario: the pricing cycle softens, organic growth falls to low single digits, integration costs run long, leverage stays near 2.9x, and a levered roll-up de-rates. −21.1%.
- Base ~$268 — 18.0x the FY2027 consensus MEAN of $14.908. Cross-check: 20.2x FY2026E; 16.0x FY2028E; 3.9% below the street's $278.89; 13.7% below the 52-week high. The scenario: AssuredPartners annualises as the consensus expects, organic growth holds mid-single-digit, leverage falls toward 2.5x, and the multiple gains a turn as the integration risk clears. +8.0%.
- Bull ~$334 — 21.5x the FY2027 consensus HIGH of $15.539. Cross-check: 7.6% above the 52-week high of $310.48; 19.9x FY2028E. The scenario: organic growth accelerates, the acquisition delivers cost synergies above plan, the balance sheet deleverages fast, and a low-beta compounder re-rates toward the multiple its larger peers command. +34.5%.
Base is 8.0% above spot; asymmetry roughly 1.64:1 (21.1% down, 34.5% up), plus a 1.09% dividend. A base under 10% and a payoff ratio under 2:1 is a Watch, and on this name it is a Watch held with unusually low confidence for the reason in Section 1.
8. Data integrity
Seven findings: two clean checks and five defects.
CLEAN 1 — capital expenditure and operating cash flow both verify against the 10-K across three years, and a corruption signature is resolved as a false positive. Vendor capex of $193.6M / $141.9M / $145.0M against the 10-K's $194M / $142M / $145M; vendor operating cash flow of $2,031.7M / $2,582.9M / $1,930.0M against $2,032M / $2,583M / $1,930M. capexToDepreciationTTM of 0.1265 falls below the 0.15 corruption threshold BUT IS CLEAN: capital expenditure genuinely is $145M while depreciation and amortisation of $1,056M is overwhelmingly amortisation of acquired intangibles from a roll-up. This is the "suspicion, not proof" case the data contract describes, tested and resolved in the company's favour. The 10-K additionally guides 2026 capital expenditure to approximately $227M, forward information absent from the payload.
CLEAN 2 — seg_geo sums to revenue exactly with the home market present. $13,942M against $13,941.8M, with UNITED STATES at $9,391M (67.4%). Both the home-market omission and the over-counting tests pass.
DEFECT 1 — netDebtToEBITDATTM, enterpriseValueTTM and the debt ratios are contaminated by FIDUCIARY CASH. Detailed in Section 2. The vendor implies $631M of net debt; the 10-Q shows corporate borrowings of $12,717M against corporate cash of $1,413M, giving $11,304M — roughly 2.85x EBITDA against a reported 0.159x, a factor of eighteen. Rejected: netDebtToEBITDATTM 0.159x, debtToEquityRatioTTM 0.0850, debtToAssetsRatioTTM 0.0247, enterpriseValueTTM $64,365M, evToSalesTTM 4.085x, evToEBITDATTM 16.225x, evToFreeCashFlowTTM 34.560x. Corrected enterprise value approximately $75,134M, 16.8% higher. This defect class — client money counted as corporate liquidity — has not previously been recorded in this programme and is specific to brokers, fiduciaries and payment processors.
DEFECT 2 — the FY2024 balance sheet reports cash of $14,987.3M and net debt of MINUS $1,502.1M, producing a $14.1 billion apparent swing into FY2025. The same fiduciary-classification problem in reverse. A reader comparing the two years would conclude Gallagher burned $13.6 billion of cash; it did not. We use the 10-Q's separated corporate figures throughout.
DEFECT 3 — totalDebt includes $515M of lease obligations, a 3.7% addition. totalDebt of $14,000M is short-term debt $866M plus long-term $12,619M plus capitalLeaseObligations $515M. The 10-Q's filed corporate borrowings are $12,717M at 2026-03-31. The mildest lease-inclusion instance in this batch and it is stated for completeness.
DEFECT 4 — seg_prod changed taxonomy in FY2024 and now mixes a segment label with revenue-type labels. Through FY2023 the block carried the genuine reportable segments summing to revenue exactly; from FY2024 it reports Commissions, Contingent Revenue, Supplemental Revenue and Investment Performance alongside a residual line still labelled "Brokerage Segment", totalling $13,778M against $13,942M — 98.8%, with $164M unaccounted for. Unusable for either purpose and not used.
DEFECT 5 — est.ebitdaAvg and est.ebitAvg carry the fixed-ratio fabrication signature. ebitdaAvg is exactly 24.356% of revenueAvg and ebitAvg exactly 17.121% in FY2025 through FY2028. Rejected; all valuation uses epsAvg.
Also noted: priceToEarningsRatioTTM of 40.67x is the GAAP figure and is arithmetically correct, but every analyst estimate in the file is on the adjusted basis, which trailed at approximately $12.01 against GAAP's $6.04 — a 1.99x gap that must be stated whenever the multiple is quoted. tangibleBookValuePerShareTTM of MINUS $36.98 and tangibleAssetValueTTM of MINUS $9,491M are CORRECT and are reported rather than rejected, because negative tangible equity is a genuine feature of a roll-up and the mechanism is disclosed. km_ttm and ratios_ttm are present and complete. km_ttm.marketCap of $63,734,320,752 differs from quote.marketCap of $63,803,683,752 by 0.11%, a trivial timing difference. quote.yearHigh/yearLow ($313.55/$190.75) against tech.hi52/lo52 ($310.48/$192.00), a 1.0% and 0.7% discrepancy; tech is used throughout. daysOfPayablesOutstandingTTM and inventoryTurnoverTTM read zero, which is correct for a broker with no inventory or trade payables of consequence.
Vendor composite rating — noted. B / 3 overall, with 4 out of 5 on discounted cash flow, return on assets and debt-to-equity, and 1 out of 5 on price-to-earnings and price-to-book. The debt-to-equity score of 4 is computed on the fiduciary-contaminated ratio rejected in DEFECT 1 and should be disregarded. The price-to-earnings score of 1 is computed on the GAAP multiple of 40.67x and is technically right and analytically misleading.
Non-equity tripwire — checked and passed. AJG is common stock, NYSE-listed since 1984-06-20. Price of $248.36 is not par-like; beta is 0.508; the dividend is variable and has grown 15.8% compound over three years; volume was 1.00M shares (roughly $249M of turnover); the 52-week band of $192.00 to $310.48 is a 62% range. This is common equity.
9. Technicals
- Price $248.36, up 0.23% on 1,001,659 shares — roughly $249 million of turnover, the lowest in this batch. Opened $244.90, ranged $240.82 to $248.82, recovering 3.1% from the day low to close near the high.
- −20.0% from the 52-week high of $310.48; +29.4% above the 52-week low of $192.00. Position within the annual range: 47th percentile.
- Above both moving averages: +6.9% above a 50-day average of $232.22 and +5.9% above a 200-day average of $234.51, with the 50-day now essentially level with the 200-day — a downtrend that has flattened.
- RSI 50.43 — almost exactly neutral. MACD +5.16, the second-most positive in this batch.
- Maximum drawdown from peak over the trailing year: −28.8%, against a 20.0% distance from the high — so roughly a third of a large decline has been recovered.
- Relative performance, and the shape is the interesting part: 3-month +20.0% against SPY +7.6% and QQQ +7.7% — the strongest three-month relative performance in this batch, by 12 points; 6-month +1.3% against SPY +11.1%; 12-month −12.6% against SPY +24.3% and QQQ +30.8% — a 37-point deficit. The turn is three months old.
- Sentiment: 19 buy, 9 hold, 1 sell across 29 analysts; consensus target $278.89 (+12.3%), median $287, high $300 (+20.8%), low $225 — 9.4% BELOW spot. This is one of only two names in this batch where the lowest analyst target is beneath the price, which means the sell side admits downside. We treat that as appropriate.
Today's move and what it does to the entry
AJG closed 2026-08-04 at $248.36, up $0.57, on the thinnest volume in this batch. There is no company-specific filing dated 2026-08-04. The most recent are the earnings 8-K of 2026-07-30 and the board 8-K of 2026-07-29.
The honest read: the entry is neither a discount nor a premium. The stock is 20% below its high and has already rallied 20% in three months. The base case is +8.0% and there is no dislocation to exploit.
10. Insiders — and a board event the payload does not carry
| Date | Person | Role | Type | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 2026-06-02 | Richard C. Cary | officer: Controller, CAO | S-Sale | 3,000 | $206.00 | 47,819.487 |
| 2026-06-22 | Douglas K. Howell | officer: VP & Chief Financial Officer | I-Discretionary (D) | 12,954.386 | $0 | 185,953.926 |
| 2026-07-01 | Vishal Jain | officer: Vice President | M-Exempt (A) | 2,162.694 | $229.57 | 68,903.384 |
| 2026-07-01 | Vishal Jain | officer: Vice President | M-Exempt (D) | 2,162.694 | $0 | 9,725.846 |
| 2026-07-01 | Thomas Joseph Gallagher | officer: President | M-Exempt (A) | 351.945 | $229.57 | 323,743.025 |
| 2026-07-01 | Thomas Joseph Gallagher | officer: President | M-Exempt (D) | 351.945 | $0 | 13,345.635 |
| 2026-07-01 | Michael Robert Pesch | officer: Vice President | M-Exempt (A) | 355.801 | $229.57 | 44,832.729 |
| 2026-07-01 | Michael Robert Pesch | officer: Vice President | M-Exempt (D) | 355.801 | $0 | 6,134.526 |
The reading, and it is thin but not empty. Six of the eight transactions are paired M-Exempt conversions on 2026-07-01 at $229.57 — mechanical option or unit settlements, not decisions. One is an I-Discretionary disposition by the Chief Financial Officer, a plan-driven transfer at zero price.
The one transaction that is a decision: Richard C. Cary, the Controller and Chief Accounting Officer, sold 3,000 shares on the open market at $206.00 on 2026-06-02, retaining 47,819.487. A 5.9% reduction, approximately $618,000, by the officer with the most complete view of the accounting. It is one transaction, it is small, it was executed 17.0% below today's price, and it is the only open-market sale in the file — we report it and build nothing on it.
Thomas Joseph Gallagher, the President, retains 323,743 shares — approximately $80.4 million — which is the substantive alignment fact.
Governance, from the 8-K filed 2026-07-29, and it is not in the payload. "On July 22, 2026, David Johnson, Lead Independent Director of the Board of Directors... passed away... On July 23, 2026, the Board reduced its size from nine to eight members. The independent directors of the Board have elected Ralph Nicoletti to serve as Lead Independent Director and the Board appointed John Coldman to the Compensation and Nominating/Governance Committees." A board of eight, of whom the President and the Chief Executive are family members sharing the company's name, warrants noting on a company that has just deployed $15.7 billion.
11. Verdict, kill-criteria and flip conditions
Watch.
The business is very good and the price is close to fair, which is the least interesting combination in research and the honest description here. At $248.36 Gallagher trades at 16.7x the FY2027 adjusted consensus of $14.908 and 14.8x FY2028's $16.760, on a 0.508-beta recurring fee business with capital expenditure of 1.0% of revenue and a geographic revenue block that ties to the income statement to the dollar. Our base of $268 is 8.0% above spot with 1.64:1 asymmetry, plus a 1.09% dividend.
Four reasons for the Watch rather than a Buy.
First, the base case is a multiple assumption. At an unchanged 16.7x the fair value is $249 — the current price. All 8.0% comes from assuming the market pays one and a third more turns.
Second, the balance sheet is more levered than any standard screen will tell you. Corporate net debt of $11,304 million at roughly 2.85x EBITDA, against a vendor reading of 0.159x contaminated by $7,069 million of client money. Tangible equity is NEGATIVE $9,956 million.
Third, the single most important operating metric for a broker — organic growth — is not in this archive. The company publishes it in a "CFO Commentary" hosted on its website and referenced but not filed. A dive that cannot see organic growth on an insurance broker is missing the number that determines everything.
Fourth, and this is the reason all three horizon confidences are Low: THE KNOWLEDGE BASE IS EMPTY. Zero claims out of 52,021. There is no independent voice to corroborate the filings, no outside read on the integration, and nothing to grade. This programme's edge is the fusion of a distilled qualitative base with disciplined quantitative work. On Arthur J. Gallagher, half of that edge does not exist, and issuing a Buy while saying so would be incoherent.
Pre-registered KILL criteria — what would take this to Avoid:
- Disclosed organic revenue growth below 3% for two consecutive quarters.
- A goodwill impairment against the $22,593 million balance, now 32.0% of total assets.
- Corporate net debt above $13 billion or leverage above 3.25x EBITDA.
- A third consecutive revenue miss after −0.3% and −1.3%.
- Another large equity-funded acquisition at a share price more than 20% below the 52-week high.
Pre-registered UPGRADE conditions — what would take this to Buy — Tactical:
- A price below roughly $215, at which the base case is +25% and the asymmetry moves through 2:1 with no change to any number here. That is 13.4% below spot and 7.4% below the 50-day average.
- Disclosed organic growth above 6% with corporate leverage below 2.5x, which together would convert this from a levered integration story into a clean compounder.
- The resumption of share repurchases after four years of none, which would signal the acquisition programme is pausing and would add to a shareholder yield that is currently 1.09%.
- Any independent knowledge-base coverage of insurance broking, which would restore the missing half of this programme's process on the name.
Where AJG sits in the Synthos Framework Portfolio. No position. On the watch list at $215, for a first tranche of 1.0% in the financials sleeve. Logged as a tracked Synthos call (Watch) as of 2026-08-04 at $248.36, with the fair-value anchors, kill criteria and upgrade conditions all gradeable. The two items worth grading this dive on are the fiduciary-cash correction — a defect class this programme had not previously recorded — and the empty knowledge-base lane, which is a finding about our coverage rather than about Gallagher and should be logged as a gap to fill.
Single biggest risk: that adjusted earnings of $12.01 and GAAP earnings of $6.04 describe the same twelve months. The $1,122.5 million of annual amortisation being excluded is genuinely non-cash and its exclusion is standard practice. It is also the accounting recognition of the $15,749 million Gallagher spent and the 16.3% of the company it issued to buy the customer relationships now being written down. A reader who accepts the adjustment without holding both facts in view is being shown 20% revenue growth and 12% earnings growth without being shown what they cost. At 16.7x the adjusted number the stock is reasonably priced; at 41.1x the reported number it is not; and the honest position is that the truth is nearer the first than the second and that the gap deserves to be stated every time the multiple is quoted.
Provenance & disclosures
- Traceability: THE KNOWLEDGE-BASE LANE IS EMPTY. Zero claims out of 52,021 name Arthur J. Gallagher & Co. A case-sensitive entity sweep on AJG, Arthur J. Gallagher, Gallagher and AssuredPartners, plus free-text searches on "gallagher" and "insurance broker", returned 0 raw hits, 0 exact matches, 0 case-insensitive matches and 0 text-only matches — nothing to discard and nothing to weight. This is reported as an empty lane per the standing rule and is NOT padded. Three notes on the void: (1) it is not a matching failure — "Gallagher" is a common surname and would produce false positives if the store held adjacent material, and it produced none; (2) the void is sector-wide, since the vendor peer set contains Aon and Marsh & McLennan and this programme has no reason to expect a different result for either, so commercial insurance distribution is simply not a subject our sources discuss; and (3) the operative consequence is that this dive has NO qualitative overlay — no independent read on the AssuredPartners integration, no view on the property and casualty pricing cycle, and no counterweight to management framing. All three horizon confidence ratings are set to Low for that reason, and the verdict is held at Watch partly because half of this programme's stated process is unavailable on this name. This should be logged as a knowledge-base coverage gap rather than as a finding about the company.
- Data as-of: fundamentals — balance sheet, fiduciary-asset disclosure and corporate borrowings through 2026-03-31 from the 10-Q filed 2026-05-07; annual statements, the capital-expenditure series and the 2026 capital guidance from the 10-K filed 2026-02-17 · June-quarter 2026 adjusted EPS and revenue from
earn_calonly, because the 8-K filed 2026-07-30 carries the earnings release as an exhibit not present in the extract · estimates 2026-08-04 · prices 2026-08-04, quote timestamp 1785873592 = 2026-08-04T19:59:52Z ($248.36, +0.23%; 50-DMA $232.22; 200-DMA $234.51; RSI 50.43; MACD +5.16) · knowledge base swept 2026-08-04 and returned nothing. Gallagher's fiscal year is the calendar year. All figures come from the Synthos vendor data file for AJG or from the SEC filings in the AJG archive. - Filing archive contents: 10-K filed 2026-02-17 (fiscal 2025 — the source of the three-year capital-expenditure series, the 2026 capital guidance of approximately $227 million, the disposition and clean-energy disclosures, and the AssuredPartners entity references); 10-Q filed 2025-11-10 (September 2025 quarter); 10-Q filed 2026-05-07 (March 2026 quarter — the source of the fiduciary-asset separation, corporate borrowings and corporate cash that correct the vendor's leverage); 8-K filed 2026-06-17 (Item 7.01 — an investor meeting held 2026-06-17 with an updated "CFO Commentary" containing 2026 estimates, hosted on the company's website and NOT in this archive); 8-K filed 2026-07-29 (Item 8.01 — the death of Lead Independent Director David Johnson on 2026-07-22, the reduction of the board from nine members to eight on 2026-07-23, and the election of Ralph Nicoletti as Lead Independent Director); 8-K filed 2026-07-30 (Item 2.02 — second-quarter results, with "Supplemental Quarterly Data" and "CFO Commentary" again hosted on the website rather than filed). The most important operating disclosure for a broker — organic growth — is in those website documents and is therefore unavailable to this dive.
- Where the filings contradicted or corrected the vendor (detailed in Section 8):
netDebtToEBITDATTMof 0.159x andenterpriseValueTTMof $64,365M, both contaminated by fiduciary cash of $7,069M that the 10-Q discloses separately as client money inside $33,873M of fiduciary assets — the filed position is corporate borrowings of $12,717M against corporate cash of $1,413M, giving $11,304M of corporate net debt and roughly 2.85x trailing EBITDA, against a vendor reading eighteen times lower, with corrected enterprise value of approximately $75,134M (+16.8%); the FY2024 balance sheet, reporting cash of $14,987.3M and net debt of MINUS $1,502.1M, producing a spurious $14.1 billion apparent swing into FY2025;totalDebtof $14,000M, which includes $515M of lease obligations (3.7%);seg_prod, which changed taxonomy in FY2024 and now mixes a segment label with revenue-type labels, totalling $13,778M against $13,942M of revenue with $164M unaccounted for;est.ebitdaAvg/ebitAvg, rejected for a fixed-ratio signature of exactly 24.356% and 17.121% of revenue in every year; andpriceToEarningsRatioTTMof 40.67x, which is the GAAP figure while every estimate in the file is adjusted, a 1.99x difference. Where vendor and filing AGREED — and one of these was a directed test: the capital-expenditure check PASSED on all three filed years ($194M/$142M/$145M, matching to rounding) and operating cash flow matched on all three ($2,032M/$2,583M/$1,930M); critically,capexToDepreciationTTMof 0.1265 trips the sub-0.15 corruption signature and is CLEAN — capital expenditure genuinely is $145M while depreciation and amortisation of $1,056M is overwhelmingly amortisation of acquired intangibles from a roll-up, which is the "suspicion, not proof" case the data contract describes, tested and resolved in the company's favour; andseg_geoPASSED, summing to $13,942M against $13,941.8M of revenue with UNITED STATES present at $9,391M (67.4%), clearing both the home-market omission and over-counting tests.km_ttmandratios_ttmare present and complete. - Basis note: all forward multiples in this dive are struck on ADJUSTED earnings per share, which is the basis of every estimate in the file — the FY2025 consensus of $10.69 against a delivered GAAP $5.75 confirms it. Trailing adjusted EPS of approximately $12.01 is the sum of the four quarterly actuals in
earn_cal; trailing GAAP EPS of approximately $6.04 is the sum of the four quarters ininc_q. The 1.99x ratio is the amortisation of acquired intangibles ($1,122.5 million in fiscal 2025) and is stated wherever a multiple appears. Free cash flow is recomputed as filed operating cash flow minus filed capital expenditure. - Estimate coverage: 13 analysts on FY2027 adjusted EPS — the anchor for all three fair values, with a range of $14.487 to $15.539, a 7.1% spread — and 12 on FY2026. But only 5 to 6 analysts cover REVENUE in any forward year, and FY2028 EPS rests on FOUR with a 28% range. The revenue array is the least well-covered load-bearing series in this batch and the FY2026 growth figure of +20.0% rests on five analysts.
- Peer note: the vendor peer set — Aflac, Aon, HDFC Bank, Manulife, Marsh & McLennan, PayPal, Sumitomo Mitsui, Travelers and Wells Fargo — contains the two relevant comparables (Aon and Marsh & McLennan) alongside two banks, an underwriter, a life insurer and a payments company. No earnings or estimate data for any peer is present in this file, only price and market capitalisation, so no peer-multiple comparison is drawn.
- Fair-value caveat: the $196 / $268 / $334 anchors are multiples of the FY2027 consensus adjusted EPS distribution — 13.5x the low of $14.48656, 18.0x the mean of $14.90762, and 21.5x the high of $15.53921 — cross-checked against the observed twelve-month multiple range of 12.9x to 20.8x, derived from the 52-week low of $192.00 and high of $310.48. Stated arithmetic, not a discounted cash flow. The base assumes MODEST MULTIPLE EXPANSION from 16.7x to 18.0x and this is named as the fragile leg: at an unchanged 16.7x the fair value is $249 — the current price — and the base upside disappears entirely.
- Timing: second-quarter 2026 results were released 2026-07-30, five days before this dive, beating the adjusted EPS consensus by 1.1% ($2.84 against $2.81) and MISSING the revenue estimate by 1.3% ($3,955M against $4,005,693K) — the second revenue miss in four quarters. The next print is 2026-10-29, 86 days away, against a consensus of $3.04 and $4,084,822K. The most recent insider filing is dated 2026-07-01; the only open-market sale in the file is 3,000 shares at $206.00 on 2026-06-02 by the Controller and Chief Accounting Officer. 2026-08-04 carried no company-specific SEC filing.
- Accessibility note: no information in this dive is conveyed by colour. All emphasis is carried by bold text, table structure and explicit labelling.
- Not investment advice. Independent research, educational and informational only, never personalised. No recommendation to buy, sell or hold any security is made to any person.
- Version: 2026-08-04-full.